OS Therapies to Acquire Certain Ayala Pharmaceuticals Assets

MT Newswires Live

Jan 29, 2025

OS Therapies (OSTX) said Wednesday it agreed to acquire Ayala Pharmaceuticals' listeria monocytogenes-based immuno-oncology programs and related intellectual property assets.

OS Therapies said it agreed to pay $500,000 in cash and issue $7.5 million worth of its common shares to Ayala under the deal, which is expected to close 60 days from the agreement's execution.

The asset purchase deal includes a phase 2 lung cancer and phase 1 prostate cancer program, on top of gaining direct ownership of the underlying IP related to OS Therapies' OST-HER2 for osteosarcoma and other HER2-related indications, the company said.

Shares of OS Therapies rose 9.3% in recent Wednesday trading.

Price: 2.84, Change: +0.24, Percent Change: +9.27

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2507630349"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507630349\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2507630349?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-29 23:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507630349","market":"hk","top_or_hot":-1,"title":"OS Therapies to Acquire Certain Ayala Pharmaceuticals Assets","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> (OSTX) said Wednesday it agreed to acquire Ayala Pharmaceuticals' listeria monocytogenes-based immuno-oncology programs and related intellectual property assets.</p><p>OS Therapies said it agreed to pay $500,000 in cash and issue $7.5 million worth of its common shares to Ayala under the deal, which is expected to close 60 days from the agreement's execution.</p><p>The asset purchase deal includes a phase 2 lung cancer and phase 1 prostate cancer program, on top of gaining direct ownership of the underlying IP related to OS Therapies' OST-HER2 for osteosarcoma and other HER2-related indications, the company said.</p><p>Shares of OS Therapies rose 9.3% in recent Wednesday trading.</p><p>Price: 2.84, Change: +0.24, Percent Change: +9.27</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OS Therapies to Acquire Certain Ayala Pharmaceuticals Assets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOS Therapies to Acquire Certain Ayala Pharmaceuticals Assets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-29 23:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> (OSTX) said Wednesday it agreed to acquire Ayala Pharmaceuticals' listeria monocytogenes-based immuno-oncology programs and related intellectual property assets.</p><p>OS Therapies said it agreed to pay $500,000 in cash and issue $7.5 million worth of its common shares to Ayala under the deal, which is expected to close 60 days from the agreement's execution.</p><p>The asset purchase deal includes a phase 2 lung cancer and phase 1 prostate cancer program, on top of gaining direct ownership of the underlying IP related to OS Therapies' OST-HER2 for osteosarcoma and other HER2-related indications, the company said.</p><p>Shares of OS Therapies rose 9.3% in recent Wednesday trading.</p><p>Price: 2.84, Change: +0.24, Percent Change: +9.27</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OSTX","symbol_name":"OS Therapies","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507630349","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507630349","pubTimestamp":1738165706,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"OS Therapies  said Wednesday it agreed to acquire Ayala Pharmaceuticals' listeria monocytogenes-based immuno-oncology programs and related intellectual property assets.OS Therapies said it agreed to pay $500,000 in cash and issue $7.5 million worth of its common shares to Ayala under the deal, which is expected to close 60 days from the agreement's execution.The asset purchase deal includes a phase 2 lung cancer and phase 1 prostate cancer program, on top of gaining direct ownership of the underlying IP related to OS Therapies' OST-HER2 for osteosarcoma and other HER2-related indications, the company said.Shares of OS Therapies rose 9.3% in recent Wednesday trading.Price: 2.84, Change: +0.24, Percent Change: +9.27","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OSTX":"OS Therapies","BK4139":"生物科技"},"translate_title":"OS Therapies将收购Ayala Pharmaceuticals的某些资产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSTX":1},"content_text":"OS Therapies (OSTX) said Wednesday it agreed to acquire Ayala Pharmaceuticals' listeria monocytogenes-based immuno-oncology programs and related intellectual property assets.OS Therapies said it agreed to pay $500,000 in cash and issue $7.5 million worth of its common shares to Ayala under the deal, which is expected to close 60 days from the agreement's execution.The asset purchase deal includes a phase 2 lung cancer and phase 1 prostate cancer program, on top of gaining direct ownership of the underlying IP related to OS Therapies' OST-HER2 for osteosarcoma and other HER2-related indications, the company said.Shares of OS Therapies rose 9.3% in recent Wednesday trading.Price: 2.84, Change: +0.24, Percent Change: +9.27","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}